Cocrystal Pharma announces IRB approval from Emory University School of Medicine for a Phase 1b human challenge study with CDI-988 for preventing and treating norovirus infections.
Enrollment for the study is expected to start in Q1 2026, marking a significant milestone in combating norovirus outbreaks.
CDI-988 is a promising oral antiviral drug candidate designed for norovirus prevention and treatment, addressing the lack of approved treatments or vaccines for norovirus infection.
Unique Drug Candidate
CDI-988 is the first oral broad-spectrum antiviral drug candidate for preventing and treating norovirus infections.
Clinical Trial Progress
The Phase 1b study will involve up to 40 healthy subjects screened and infected with norovirus, assessing clinical symptom reduction and viral shedding.
Innovative Approach
Cocrystal's structure-based drug discovery platform technology enabled the development of CDI-988, showing promising safety and tolerability data in Phase 1 trials.
- The Emory University collaboration and FDA approval demonstrate Cocrystal's commitment to advancing norovirus treatment.
- CDI-988's potential as a prophylactic solution could revolutionize norovirus management in various high-risk environments.
Cocrystal's groundbreaking Phase 1b study with CDI-988 reflects its dedication to combating norovirus outbreaks and offering innovative solutions for this global health challenge.